• The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.
• Most patients are diagnosed with mesothelioma late, resulting in a median overall survival of just 12 to 18 months.1
• Roche's comprehensive cancer diagnostic portfolio delivers end-to-end clinical answers across the patient journey, spanning advanced tissue diagnostics, core lab immunoassays, molecular testing and digital diagnostics.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.